



DIASORIN S.P.A., THE ORDINARY SHAREHOLDERS' MEETING APPROVES THE 2008 STATUTORY FINANCIAL STATEMENTS AND THE DIVIDEND DISTRIBUTION.

Saluggia, April 28, 2009 – The Ordinary Shareholders' Meeting, convened under the chairmanship of Gustavo Denegri, was attended by shareholders representing 67.592% of the Company's share capital, who record the Group's results, reviewed and approved the statutory financial statements at December 31, 2008 and the dividend distribution motion.

In the course of the Shareholders' Meeting, Carlo Rosa, the Chief Executive Officer of Diasorin S.p.A., presented and commented the Group's results: revenues grew to 244.5 million euros, for a gain of 20.9% compared with 2007; margins continued to improve, causing EBIT to rise by 41.1% (net of the nonrecurring charges/income recognized in 2007) to a total of 70.8 million euros (equal to 28.9% of revenues); net profit rose to 37.5 million euros, for an increase of 48.5% compared with 2007.

Then the Shareholders' Meeting reviewed and approved the statutory financial statements at December 31, 2008 ended with revenues of 129.3 million euros, or 10.5% more than in 2007, and a net profit that, at 25.7 million euros, was more than double the 10.0 million euros earned in 2007.

Lastly, the Shareholders' Meeting also approved a motion to distribute a dividend of 0.12 euros per share, with June 15, 2009 record date and June 18, 2009 payable date.



About Diasorin

Diasorin S.p.A., an international player in the market for in vitro diagnostics, develops, produces and markets reagent kits for clinical laboratory diagnostics. The Diasorin Group comprises 15 companies based in Europe, the United States, Central and South America and Asia. It has more than 1,000 employees, including 90 research and development specialists, and operates four manufacturing and research facilities in Saluggia (Vercelli, Italy), Dietzenbach (Germany), Stillwater (USA) and Dublin (Ireland). Thanks to its direct sales organization and an international network of over 80 independent distributors, the Group is present in more than 60 countries, offering a broad array of high quality products that includes comprehensive lines for each of the clinical segments in which the Group operates: infectious and viral diseases, management of bone and calcium related diseases, thyroid pathologies, oncology and fertility testing.

For additional information, please visit our website: www.diasorin.com

Contacts:

Investor Relations Officer

Laura Villa

DiaSorin S.p.A.

laura.villa@diasorin.it

+39 0161487532

+39 348 15 11 542

Press Office

Carolina Mailander

c.mailander@mailander.it

+39 335 655 56 51

Bruno Caprioli

caprioli@mailander.it

+39 335 590 14 02